Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company

MSD Plans to Introduce Over 50 New Drugs and Vaccines to China in the Next Five Years

Fineline Cube Sep 8, 2023

Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK), through its China R&D president Li Zhengqing,...

Company Deals R&D

Novo Nordisk and Broad Institute Collaborate on Diabetes and Cardiometabolic Research

Fineline Cube Sep 7, 2023

Denmark-based pharmaceutical giant Novo Nordisk (NYSE: NVO) has announced a collaboration with the US academic...

Company Drug

Janssen’s Rybrevant Combo Meets Primary Endpoint in Advanced NSCLC Study

Fineline Cube Sep 7, 2023

Janssen, a subsidiary of Johnson & Johnson (J&J; NYSE: JNJ), has released an update on...

Company Policy / Regulatory

FDA Addresses Looming Migraine Treatment Shortage with Tonix Pharmaceuticals Commitment

Fineline Cube Sep 7, 2023

The US Food and Drug Administration (FDA) is actively engaging with pharmaceutical companies to address...

Company Drug

Henan Zhongshuai’s Dexmethylphenidate Hydrochloride Capsules Target Priority Review for Pediatric ADHD

Fineline Cube Sep 7, 2023

Henan Zhongshuai Pharmaceutical Co., Ltd., a China-based pharmaceutical company, is poised to secure priority review...

Company Drug

Amneal Pharmaceuticals Receives China Approval for Sevelamer Carbonate

Fineline Cube Sep 7, 2023

US-based Amneal Pharmaceuticals Inc. (NYSE: AMRX) has announced that it has received approval from the...

Company Drug

CSPC Pharmaceutical’s Narlumosbart Approved by NMPA for Bone Giant Cell Tumors

Fineline Cube Sep 7, 2023

CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its subsidiary, Shanghai JMT Biotechnology Co.,...

Company Drug

Jiangsu Hengrui’s HER2-Targeted ADC SHR-A1811 Aims for CDE’s BTD Status

Fineline Cube Sep 7, 2023

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its HER2 targeted antibody-drug...

Policy / Regulatory

NMPA Drafts Guidelines for Supervising Online Drug Exchange Platforms

Fineline Cube Sep 7, 2023

The National Medical Products Administration (NMPA) has released draft “Online Third-party Drug Exchange Platforms Inspection...

Company Drug

Genentech Files for FDA Approval of Crovalimab for PNH, Challenging Soliris

Fineline Cube Sep 7, 2023

Swiss pharmaceutical giant Roche’s subsidiary, Genentech (SWX: ROG), has submitted its anti-C5 investigational drug, crovalimab,...

Company Deals

uBriGene and YolTech Therapeutics Join Forces to Advance mRNA Therapy and Gene Therapy

Fineline Cube Sep 7, 2023

China-based uBriGene Biosciences Inc., a prominent contract development and manufacturing organization (CDMO) specializing in cell...

Policy / Regulatory

CDE’s 2022 Drug Review Report: A Year of Pandemic Response and Regulatory Milestones

Fineline Cube Sep 7, 2023

The Center for Drug Evaluation (CDE) has released its comprehensive 2022 annual drug review report,...

Company Drug

Hainan Haiyao Concludes Phase I Clinical Study for PaiEnJiaBin, a Novel KCNQ Agonist

Fineline Cube Sep 7, 2023

China-based Hainan Haiyao Co., Ltd (SHE: 000566) has announced the conclusion of Phase I clinical...

Company Deals

Sino Medical Sciences Technology to Acquire Majority Stake in US Endovascular Device Firm eLum

Fineline Cube Sep 7, 2023

China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced plans to acquire a 72.73%...

Company Medical Device

Acotec Scientific Holdings Receives Marketing Approvals for Vericor-14 Microcatheter in Japan and Thailand

Fineline Cube Sep 7, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approvals...

Company Drug

Brii Biosciences Announces Positive Interim Data for BRII-179 Vaccine in Chronic Hepatitis B

Fineline Cube Sep 7, 2023

China-based Brii Biosciences Ltd (HKG: 2137) has announced topline cohort-level unblinded Week 36 data from...

Company Drug

MSD’s Gardasil 9 HPV Vaccine Demonstrates 10-Year Efficacy in Adolescents

Fineline Cube Sep 6, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has released long-term effectiveness data for its recombinant...

Company Deals

Sinovac Biotech Directors Reject Alternative Liquidity’s Lowball Tender Offer

Fineline Cube Sep 6, 2023

China-based Sinovac Biotech Ltd. (NASDAQ: SVA) announced that its Board of Directors has unanimously determined...

Company Deals

Abbott to Acquire Insulin Management Firm Bigfoot Biomedical

Fineline Cube Sep 6, 2023

Healthcare giant Abbott (NYSE: ABT) has announced an agreement to purchase Bigfoot Biomedical, a company...

Policy / Regulatory

Taizhou Port Designated as Drug Import Port by NMPA and General Administration of Customs

Fineline Cube Sep 6, 2023

The National Medical Products Administration (NMPA) and the General Administration of Customs have released a...

Posts pagination

1 … 477 478 479 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.